
Kluwer Patent Blog

IBSA Institut Biochimique SA v. Pharmacia & Upjohn in liquidazione and Pfizer Italia s.r.l., District Court Milan (Tribunale Milano), 26 May 2009

Daniela Ampollini (Trevisan & Cuonzo) · Saturday, June 11th, 2011

The Milan Court revoked a patent on the second medical use of a known drug because excerpts of the protocol of the clinical trials aimed at proving efficacy of the second use had been published before the relevant date in a scientific journal. The Court held that the outcome of the trials - which later became the subject matter of the patent - could not be considered surprising in view of the protocol described in the publication. Furthermore there could have been no prejudice because the first and second use of the known product were aimed at patients having diseases of the same type. In particular the carrying out - as such - of experiments cannot contribute to inventive step.


A **full summary** of this case has been published on **Kluwer IP Law**.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2021 Future Ready Lawyer survey** showed that 81% of the law firms expect to view technology as an important investment in their future ability to thrive. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.



This entry was posted on Saturday, June 11th, 2011 at 4:16 pm and is filed under [Biologics](#), [Case Law](#), [Inventive step](#), [Italy](#)
You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.